Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer, Jeffrey B. Kindler, at the 33rd Annual Deutsche Bank Healthcare Conference on Monday, May 5th at 12:40pm Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “Deutsche Bank Healthcare
You are here
Press Release Archive
(BUSINESS WIRE)--Pfizer has entered into a collaboration agreement with four major research universities – University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and University of Massachusetts – and Entelos, a physiological modeling company, to re-examine the regulatory mechanisms of human energy metabolism. Pfizer is funding the three-year and $14 million Insulin
The board of directors of Pfizer Inc today declared a 32-cent second–quarter, 2008, dividend on the company’s common stock, payable June 3, 2008, to shareholders of record at the close of business on May 9, 2008. The second-quarter 2008 cash dividend will be the 278th consecutive quarterly dividend paid by Pfizer, and 2008 marks the 41st consecutive year of annual dividend increases for Pfizer
(BUSINESS WIRE)--Today at Pfizer’s annual shareholder meeting, Chairman and Chief Executive Officer Jeffrey B. Kindler detailed his plan to build on the Company’s foundation to drive greater shareholder return. “Operationally, in 2007, we took a series of significant actions to better position Pfizer to meet our challenges and to seize the many opportunities before us in the growing global marketplace
(BUSINESS WIRE)--Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal. Specifically, Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering the following categories
(BUSINESS WIRE)--Pfizer Inc announced today that on May 8, 2008, it will launch Champix® Tablet 0.5mg/1mg (varenicline tartrate), a novel smoking cessation aid for smokers with nicotine dependence in Japan, which has one of the highest rates of smoking among developed nations. Champix was developed as the first non-nicotine drug designed for smoking cessation in the United States and will be the first oral smoking cessation aid
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, April 24. To access the webcast, visit our Web site at www.pfizer.com and click on the “Annual Meeting of Shareholders” webcast link in the Investor Presentations tab on our homepage. Information on accessing and pre-registering for the webcast will be
Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg reduced the risk of heart attack and stroke by 32 percent in patients who have heart disease and chronic kidney disease compared with patients taking the 10 mg dose of Lipitor. This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study, was published in the “Journal of the American
Pfizer Japan Inc announced that on April 16, the company received an approval for the manufacturing and marketing authorization of the anti-tumor drug/kinase inhibitor “SUTENT® Capsule 12.5 mg” (sunitinib malate) indicated for Gastrointestinal Stromal Tumor (GIST) after failure of imatinib treatment due to resistance and for Renal Cell Carcinoma (RCC) not indicated for curative resection and Metastatic Renal
(BUSINESS WIRE)--A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of its annual $300 million (US dollar) commitment to research and development. The new centre is located on the Louvain-la-Neuve scientific plant near Brussels. "This is an historic occasion for Pfizer Animal Health,” said Juan Ramon
(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience’s proposed product in Canada until Pfizer’s amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appeal
(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg to Aricept® (donepezil HCl) 10 mg showed no significant differences in cognition or global function (key measures of Alzheimer’s progression) compared to placebo plus Aricept 10 mg. Furthermore, no statistically significant differences were seen on various cognitive, behavioral
Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting. The analysis, which looked at data pooled from previous clinical trials, also showed that patients’ self-reported improvements were more closely associated
(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes, expired as of 5:00 p.m., New York
(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera. This update is based on an ongoing review of the data from the Exubera clinical trial program and post-marketing experience by Pfizer and the Food and Drug Administration (FDA)
(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has extended the subsequent offering period of its tender offer for all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) to 5:00 p.m., New York City time, on April 14, 2008. Pursuant to the tender offer, Explorer Acquisition Corp. is offering to purchase shares of Encysive at
(BUSINESS WIRE)--On April 1, 2008, Pfizer Inc (NYSE: PFE) announced results of its tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes. Pursuant to information received from the
(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III clinical trial (A3671009), of single-agent tremelimumab (CP-675,206) in patients with advanced melanoma, after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. Pfizer has communicated with worldwide regulatory authorities and investigators regarding the discontinuation of the trial. Investigators
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.